Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DH6G1L
|
|||
| Drug Name |
APH-1105
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Aphios
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-secretase (ASE) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03806478) Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD). U.S.National Institutes of Health. | |||
| REF 2 | Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021 May 25;7(1):e12179. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.